Company: ZVRA
Filing Date: 2025-11-05
Form Type: 10-Q
Source: 0001434647-25-000011
Chunk: 49

Company: ZEVRA THERAPEUTICS, INC.
Filing Date: 2025-11-05
Form: 10-Q
Item: Part I, Item 1
Chunk 49
---
 and 53,670,709 shares outstanding as of December 31, 20246 5 Additional paid-in capital580,783 555,302 Treasury stock, at cost(10,983)(10,983)Accumulated deficit(434,225)(505,289)Accumulated other comprehensive (loss) income(2,416)631 Total stockholders' equity133,165 39,666 Total liabilities and stockholders' equity$270,116 $178,127 

See accompanying notes to unaudited condensed consolidated financial statements.

4

Table of Contents

ZEVRA THERAPEUTICS, INC.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except share and per share amounts)

Three months ended September 30,Nine months ended September 30,2025202420252024Revenue, net$26,063 $3,695 $72,345 $11,569 Cost of product revenue (excluding $315 and $1,545 in intangible asset amortization for the three months ended September 30, 2025, and 2024, respectively, and $3,546 and $4,619 in intangible asset amortization for the nine months ended September 30, 2025, and 2024, respectively, shown separately below)1,238 2,303 14,962 6,051 Intangible asset amortization315 1,545 3,546 4,619 Impairment of intangible assets— — 58,710 — Operating expenses:Research and development3,432 10,945 10,123 33,743 Selling, general and administrative16,935 16,208 57,262 38,743 Total operating expenses20,367 27,153 67,385 72,486 Income (loss) from operations4,143 (27,306)(72,258)(71,587)Other (expense) income:Gain on sale of PRV— — 148,325 — Interest expense(2,051)(2,312)(6,029)(5,157)Fair value adjustment related to warrant and CVR liability(5,506)(4,746)(1,379)4,660 Fair value adjustment related to investments124 90 119 64 Interest and other income, net2